December 21, 2011
On December 21, 2011, the Food and Drug Administration approved dosing recommendations for Isentress (raltegravir) for pediatric patients ages 2 to 18 years and weighing at least 10 kg. In addition a 100 mg scored chewable tablet and 25 mg chewable tablet was approved for use in pediatric patients.
The Dosage and Administration section includes the following general dosing recommendations and dosing recommendations for pediatrics.
General Dosing Recommendations
For the treatment of children and adolescents with HIV-1 infection, the dosage of ISENTRESS is as follows:
The following was added to Section 5 WARNINGS AND PRECAUTIONS:
ISENTRESS chewable tablets contain phenylalanine, a component of aspartame. Each 25 mg ISENTRESS chewable tablet contains approximately 0.05 mg phenylalanine. Each 100 mg ISENTRESS chewable tablet contains approximately 0.10 mg phenylalanine. Phenylalanine can be harmful to patients with phenylketonuria.
The following was added to Section 6 ADVERSE REACTIONS:
6.5 Clinical Trials Experience: Pediatrics
ISENTRESS has been studied in 126 antiretroviral treatment-experienced HIV-1 infected children and adolescents 2 through 18 years of age, in combination with other antiretroviral agents in IMPAACT P1066. Of the 126 patients, 96 received the recommended dose of ISENTRESS.
In these 96 children and adolescents, frequency, type and severity of drug related adverse reactions through Week 24 were comparable to those observed in adults.
One patient experienced drug related clinical adverse reactions of Grade 3 psychomotor hyperactivity, abnormal behavior and insomnia; one patient experienced a Grade 2 serious drug related allergic rash.
One patient experienced drug related laboratory abnormalities, Grade 4 AST and Grade 3 ALT, which were considered serious.
The following text was added to Section 7 Drug Interactions subsection 7.2:
The following information was added to Section 8.4 Pediatric Use:
8.4 Pediatric Use
The safety, tolerability, pharmacokinetic profile, and efficacy of ISENTRESS were evaluated in HIV-1 infected children and adolescents 2 to 18 years of age in an open-label, multicenter clinical trial, IMPAACT P1066. The safety profile was comparable to that observed in adults. See Dosage and Administration for dosing recommendations for children 2 years of age and older. Safety and effectiveness of ISENTRESS in children under 2 years of age have not been established.
The following information was added to Section 12.3 Pharmacokinetics:
Q95K/R was added to list of substitutions under 12.4 Microbiology/Antiviral Activity in Cell Culture section.
The following was added under Section 14 CLINICAL STUDIES:
14.3 Pediatric Subjects
IMPAACT P1066 is a Phase I/II open label multicenter trial to evaluate the pharmacokinetic profile, safety, tolerability, and efficacy of raltegravir in HIV infected children. This study enrolled 126 treatment experienced children and adolescents 2 to 18 years of age. Subjects were stratified by age, enrolling adolescents first and then successively younger children. Subjects received either the 400 mg film-coated tablet formulation (6 to 18 years of age) or the chewable tablet formulation (2 to less than 12 years of age). Raltegravir was administered with an optimized background regimen.
The initial dose finding stage included intensive pharmacokinetic evaluation. Dose selection was based upon achieving similar raltegravir plasma exposure and trough concentration as seen in adults, and acceptable short term safety. After dose selection, additional subjects were enrolled for evaluation of long term safety, tolerability and efficacy. Of the 126 subjects, 96 received the recommended dose of ISENTRESS [see Dosage and Administration (2.3)].
These 96 subjects had a median age of 13 (range 2 to 18) years, were 51% Female, 34% Caucasian, and 59% Black. At baseline, mean plasma HIV-1 RNA was 4.3 log10 copies/mL, median CD4 cell count was 481 cells/mm3 (range: 0 - 2361) and median CD4% was 23.3% (range: 0 - 44). Overall, 8% had baseline plasma HIV-1 RNA >100,000 copies/mL and 59% had a CDC HIV clinical classification of category B or C. Most subjects had previously used at least one NNRTI (78%) or one PI (83%).
Ninety-three (97%) subjects 2 to 18 years of age completed 24 weeks of treatment (3 discontinued due to non-compliance). At Week 24, 54% achieved HIV RNA <50 copies/mL; 72% achieved HIV RNA <400 copies/mL or =1 log10 HIV RNA drop from baseline. The mean CD4 count (percent) increase from baseline to Week 24 was 119 cells/mm3 (3.8%).
Isentress is an HIV integrase strand transfer inhibitor manufactured by Merck & Co., Inc.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.